Several ICI antibodies targeting CTLA-4 or the PD-L1/PD-1 axis are approved for use by the Food and Drug Administration (FDA) and European Medicines Agency (EMA) for treatment of different cancer types. This evidence concerns the gene CD274 and cancer.